Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients

Infertility Clinical Trial

Official title:

An Efficacy and Safety Study of Corifollitropin Alfa Versus Daily Follitropin Beta for Controlled Ovarian Stimulation in Women 35-42 Years Old With a Body Weight ≥ 50 kg Undergoing IVF Treatment.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02466204
• Other study ID #: NCKH/CGRH_ 01_2015
• Status: Completed
• Phase: Phase 4
• First received: June 2, 2015
• Last updated: August 21, 2017
• Start date: June 1, 2015
• Est. completion date: August 15, 2017

Study information

• Verified date: August 2017
• Source: Vietnam National University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A prospective, randomized, controlled study to explore the efficacy and safety of using either corifollitropin alfa 150 mcg or daily recombinant follicle stimulation hormone (FSH) 300 international unit (IU) for the stimulation treatment of subjects undergoing controlled ovarian stimulation prior to IVF.

The study is designed as a non-inferiority trial. The sample size for this trial of 400 subjects, in both groups, being treated for one IVF cycle is based upon the primary endpoint of the number of oocytes retrieved.

Description:

Stimulation regimen and assisted reproductive technology procedures

Corifollitropin Alfa Group: On day 2 or day 3 of the menstrual cycle, a single subcutaneous injection of corifollitropin alfa 150 mg/ 0.5 mL is administered (stimulation day 1).

FSH Group: Daily subcutaneous injections with recombinant FSH (Follitropin Beta) 300 international units (IU) is started on On day 2 or day 3 of the menstrual cycle (stimulation day 1) and continue up to and including stimulation day 7.

From stimulation day 8 onwards, subjects from both treatment groups will continue with a daily subcutaneous dose of FSH up to the day before human chorionic gonadotropin (hCG) administration or gonadotropin releasing hormone agonist administration day. The maximum FSH dose to continue treatment after the first 7 days is 300 IU, but the dose could be reduced when desired.

To prevent premature luteinizing hormone (LH) surges the gonadotropin releasing hormone (GnRH) antagonist (ganirelix acetate subcutaneous injection, 0.25 mg/ 0.5 mL) is administered, starting on stimulation day 5.

As soon as at least three follicles of 17 mm are observed by ultrasound, hCG or a GnRH agonist will be used for final oocyte maturation at the same day. hCG is used if 3-18 follicles and 0.2 mg triptorelin is administered if ≥ 19 follicles >11 mm are observed. About 34-36 hours thereafter, oocyte retrieval followed by IVF or intra-cytoplasmic sperm injection (ICSI) is performed. Three days after oocyte pick-up, 2 to 3 fresh embryos will be transferred. If patients have high progesterone level on day of trigger (progesterone level > 1,5 ng/ml), risk of OHSS and unfavorable endometrium, fresh transfers will be cancelled and freeze all will be recommended.

Patients using hCG for final oocyte maturation will receive luteal phase support with progestogen gel (90 mg once daily) intra-vaginally and estradiol (4 mg/day orally, twice daily) initiated on the day of oocyte retrieval or the day thereafter. Patients, using GnRH agonist for triggering, will have fresh transfer with intense luteal phase support of estradiol and progesterone (receive intense luteal phase support with estradiol and progesterone as the same dose mentioned above and progesterone 50 mg intramuscular injection per day).

Assessments

Patients will return to the clinic for pregnancy test 2 weeks after embryo transfers.

Local tolerance parameters (pain, itching, swelling and redness) are assessed by the clinical staff 30 min after injection for both corifollitropin alfa and FSH injection sites.

Clinical Outcome The primary objective is to show that the corifollitropin alfa regimen, in terms of the number of oocytes retrieved, is equivalent to the reference treatment (predefined equivalence range: -3 to +5 oocytes).

Other clinical parameters will also be evaluated: dose of FSH required, duration of stimulation, number and size of follicles (≥11mm and ≥14 mm), serum hormone levels, fertilization rate, number and quality of embryos obtained, implantation rate, miscarriage rate, and pregnancy rates.

At least 14 days after embryo transfer, a blood pregnancy test is performed. If the pregnancy test is positive, vaginal and/or abdominal ultrasonographic investigation is performed between 35 and 42 days ( 5 to 6 weeks) after embryo transfer to confirm a clinical pregnancy and at least 70 days (≥ 10 weeks) after embryo transfer to confirm an ongoing pregnancy.

Patients will be followed to one year after randomization.

All efficacy analyses will be based on the intent-to-treat (ITT) population, which included all randomized patients who will receive corifollitropin alfa or at least one dose of FSH

Safety endpoints

Occurrence of adverse events, including moderate and severe ovarian hyperstimulation syndrome (OHSS), outcome of local tolerance at injection site assessments will be evaluated as safety endpoints.

The percentage of patients with moderate or severe OHSS and local tolerance is compared between the treatment groups using Fisher's exact test.

Safety analyses will be performed on the all-subjects-treated group, which comprised all the patients who will receive either corifollitropin alfa or FSH.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 400
• Est. completion date: August 15, 2017
• Est. primary completion date: August 10, 2016
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 35 Years to 42 Years

Eligibility

Inclusion Criteria:

• Each subject must be willing and able to provide written informed consent for the study.

• Each subject must be female with years of age =35 to =42 at the time of recruitment..

• Each subject must have an indication for controlled ovarian stimulation and IVF

• Each subject must have a body weight = 50.0 kg, with a body mass index (BMI) =18.0 to =32.0 kg/m2.

• Each subject must have a regular spontaneous menstrual cycle with an intra-individual variation not outside the 24 to 35 days range.

• For each subject, ejaculatory sperm must be available (use of donated and/or cryopreserved sperm is allowed; sperm obtained via surgical sperm retrieval is not allowed).

• Each subject must have results of clinical laboratory test (complete blood count, blood chemistries, and urinalysis) within normal limits or clinically acceptable to the investigator, as measured by the local laboratory at screening. A normal cervical smear result, obtained within 12 months, otherwise it must be obtained during screening.

• Each subject must have results of a physical examination, including blood pressure, within normal limits or clinically acceptable limits to the investigator.

• Each subject must have normal ovarian reserve, based on anti-Mullerian hormon (AMH) of 1.38 - 3.25ng/ml or an antral follicle count (AFC) of 7-20, taken within 2 months prior to corifollitropin alfa start.

• Each subject must be able to adhere to dose and visit schedules and willing to disclose any medical events to the investigator.

Exclusion Criteria:

• The subject has a recent (ie, within 3 years) history of/ or any current endocrine abnormality (irrespective whether the patient is stabilized on treatment).

• The subject has a history of ovarian hyper-response (ie, previous IVF cycle with more than 30 follicles =11 mm on ultrasound) or ovarian hyperstimulation syndrome (OHSS).

• The subject has a history of/or current polycystic ovary syndrome (PCOS)

• The subject has more 20 basal antral follicles <11 mm (both ovaries combined) as measured on ultrasound in the early follicle phase (menstrual cycle day 2-5).

• The subject has less than 2 ovaries in any other ovarian abnormality (including endometrioma > 10 mm; visible on ultrasound).

• The subject has unilateral or bilateral hydrosalpinx (visible on ultrasound, less clipped).

• The subject has any intra-uterine fibroids >5 cm or any clinically relevant pathology, which could impair embryo implantation or pregnancy continuation.

• The subject has more than three unsuccessful treatment cycles for IVF/ICSI.

• The subject has a history of non- or low avarian response to FSH / Human Menopausal Gonadotropin (hMG) treatment (ie, previous COS cycle cancelled due to insufficient ovarian response or =3 oocytes obtained).

• The subject has a history of current miscarriage (3 or more, even when explained).

• The subject has FSH > 15.0 IU/L or LH > 12 .0 IU/L as measured by the local laboratory (sample taken during the early follicle phase: menstrual cycle day 2 to 5).

• The subject has tested positive for human immunodeficiency virus (HIV) or Hepatitis B (results obtained within one year) .

• The subject has contra-indications for the use of gonadotropins (eg, tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, or ovarian cysts) or GnRH antagonist (eg, hypersensitivity, pregnancy/lactation).

• The subject has a concomitant use of either LH or hMG/urinary FSH preparations in study cycle.

• The subject has a recent history of/or current epilepsy, thrombophilia, diabetes, cardiovascular, gastro-intestinal, hepatic, renal or pulmonary or auto-immune disease requiring regular treatment.

• The subject or the sperm donor has known gene defects, genetic abnormalities, or abnormal karyotyping, relevant for the current indications or for the health of the offspring.

• The subject smokes or has recently stopped smoking (ie, within the last 3 months prior to signing ICF).

• The subject has a history or presence of alcohol or drug abuse within 12 months prior to signing informed consent.

• The subject has an allergy/ sensitivity to investigational drugs or their excipients.

• The subject has used any experimental drugs within 3 months prior to signing informed consent.

• The subject is participating in any other clinical study (excluding surveys).

Related Conditions & MeSH terms

• Infertility

Intervention

Drug:
• corifollitropin alfa
Drug is injected subcutaneously. Seven days after, 300 IU FSH daily injected subcutaneously, until at least two leading ovarian follicles reach 17mm in diameter.
• Follitropin Beta
Drug is injected subcutaneously, daily, until at least two leading ovarian follicles reach 17mm in diameter.

Locations

Country	Name	City	State
Vietnam	My Duc Hospital	Ho Chi Minh City
Vietnam	Research Center for Genetics and Reproductive Health	Ho Chi Minh City

Sponsors (3)

Lead Sponsor	Collaborator
Vietnam National University	M? Ð?c Hospital, Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

Vietnam, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of oocytes	in 10 minutes after oocyte retrieval, total number of oocytes retrieved is counted and recorded	10 minutes after oocyte retrieval completed
Secondary	Rate of moderate and severe ovarian hyperstimulation syndrome	symptoms of ovarian hyperstimulation syndrome are followed and recorded until 8 days after oocyte retrieval.	8 days after oocyte retrieval
Secondary	Live birth	delivery of live birth	at the time of delivery
Secondary	number of MII oocytes	Number of mature oocytes collected	2 hours after oocyte retrieval completed
Secondary	number of 2PN	number of two pronuclear (2PN) fertilized oocytes	18 hours after sperm injection
Secondary	number of mature follicles >11 mm	number of mature follicles >11 mm in diameter	on the day of hCG administration
Secondary	estradiol level	serum level of estradiol	on the day of hCG administration
Secondary	FSH dose	total dose of FSH	calculated on the day of hCG administration
Secondary	implantation rate	number of sacs with heart beat per total number of embryos transferred	5 to 6 weeks after embryo transfer
Secondary	Clinical pregnancy	gestational sac on ultrasound	at 5 to 6 six weeks after embryo transfer
Secondary	Ectopic pregnancy	The presence of a gestational sac outside the uterine cavity shown on sonography or laparoscopy	7 to 8 weeks after embryo transfer
Secondary	Miscarriage	Loss of clinical pregnancy	7 to 12 weeks of gestation
Secondary	Multiple pregnancy	more than one gestational sacs or heart beats on ultrasound	at 7 weeks of gestation
Secondary	Ongoing pregnancy	At least one gestational sac on ultrasound	at 10 weeks after embryo transfer
Secondary	Cumulative ongoing pregnancy	Cumulative ongoing pregnancy at 12 months after randomization	at 12 months after randomization
Secondary	Pregnancy-induced hypertension	systolic blood pressure =140 mmHg or diastolic pressure =90 mmHg on two occasions, two hours apart, or severely elevated single blood pressure measurement requiring antihypertensive medication	measured at or after 20 weeks gestation
Secondary	Pre-eclampsia	hypertension plus proteinuria or other organ involvement, neurologic or hematologic complications, uteroplacental dysfunction, or fetal growth restriction	measured at or after 20 weeks gestation
Secondary	HELLP syndrome	Elevated liver enzyme levels (aspartate aminotransferase =100 U/L), thrombocytopenia (platelet count <100,000/mm3), elevated serum creatinine level (=1.5 mg/dL [132.6 µmol/L]) and/or hemolysis (hemoglobin <10 g/dL)	measured at or after 20 weeks gestation
Secondary	Gestational diabetes mellitus	Diagnosed using a 75g oral glucose tolerance test; fasting: 92 mg/dL [5.1 mmol/L]; 2-hour: 153 mg/dL [8.5 mmol/L]	measured at or after 20 weeks gestation
Secondary	Prematurity	preterm birth if any	at 24 weeks gestation, at 32 weeks gestation, at 34 weeks gestation, and at 37 weeks' gestation
Secondary	Cumulative live birth	cumulative live birth delivery at 12 months after randomization	at 12 months after randomization